Table 4.
Bivariate analysis of factors associated with attainment of therapeutic free levels
| Variable | Odds ratio (95% CI) | P value |
|---|---|---|
| Equation dosing | 0.65 (0.32–1.30) | 0.22 |
| Equation without Vd + SF | 2.10 (1.08–4.01) | 0.03 |
| Provider dosing | 0.62 (0.28–1.32) | 0.21 |
| BMI ≥ 30 | 0.85 (0.44–1.61) | 0.61 |
| Renal dysfunction | 0.57 (0.28–1.16) | 0.12 |
| Liver dysfunction | 0.71 (0.19–2.61) | 0.60 |
| Concomitant ASA | 0.75 (0.94–4.70) | 0.07 |
| Concomitant dexamethasone | 0.84 (0.36–1.94) | 0.68 |
| Concomitant phenobarbital | 0.77 (0.37–1.48) | 0.43 |
| Concomitant VPA | 1.09 (0.38–3.08) | 0.87 |
ASA acetylsalicylic acid (aspirin), BMI body mass index, CI confidence interval, SF salt formulation, Vd volume of distribution, VPA valproic acid